Compass Therapeutics Corp (CMPX): Long-Term Debt to Capital Ratio

Compass Therapeutics - graphic logo of issuer CMPX

Compass Therapeutics (CMPX) faces threats due to high development costs and testing uncertainty, with the indicator standing at 0.05. The price action for the company available on the GURU.Markets chart complements data regarding the expansion of programs to create complex tumor medications. Management, consisting of experts and scientists, effectively coordinates a portfolio of innovative antibodies for oncology treatment.

CMPX - Compass Therapeutics Long-Term Debt to Equity over the range 07/04/2022 - 10/27/2026

Compass Therapeutics (CMPX) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price Compass Therapeutics Inc|CMPX - Price Target Chart
- market capitalization data:
Market Capitalization Compass Therapeutics, Inc.|CMPX - Enterprise Value
- book capitalization data:
Accounting Value per Share Compass Therapeutics|CMPX - Company Book Value|Market-to-Book Ratio compasstherapeutics.com|CMPX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Compass Therapeutics|CMPX - Long-Term Debt to Equity|Current Liabilities to Capital compasstherapeutics.com|CMPX - Company Aggregate Debts|Debt to Net Assets Compass Therapeutics, Inc.
Fundamental company valuation:CMPX Compass Therapeutics Inc
Brand item of Compass Bio

This indicator assesses long-term financial stability by comparing liabilities with maturities exceeding one year against total equity to determine the degree of debt load. The trend of the long-term debt-to-equity ratio reflects the balance between debt financing and investment, which for Compass Therapeutics (CMPX) is confirmed by the absence of asset depreciation and planned laboratory utilization without excessive leverage.

Who Compass Therapeutics competes with

Long-Term Liabilities to Capital IBRX|Long-Term Debt to Equity Immunocore PLC IMCR|Long-Term Debt to Capital Ratio Janux Corp (JANX)|Arcus Biosciences, Inc. - Long-Term Debt to Capital|zymeworks.com - Long-Term Debt to Equity Ratio|TNGX (Tango Therapeutics, Inc.) - Long-Term Debt to Equity|IOVA: Long-Term Liabilities to Capital|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity REPL (Replimune Group, Inc.)|Long-Term Liabilities to Capital lyell.com|IPHA: Long-Term Debt to Capital|Long-Term Indebtedness to Equity pyxisoncology.com PYXS|CGEN: Long-Term Debt to Equity Ratio|IOBT - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio Sutro Biopharma, Inc. (STRO)|INKT - Long-Term Debt to Capital Coefficient|werewolftx.com - Long-Term Debt to Capital|IMMX (Immix Biopharma) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALXO|Long-Term Debt to Equity Ratio CUE|Long-Term Debt to Equity PDSB (PDS Biotechnology)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|Long-Term Debt to Equity Ratio MAIA (MAIA Biotechnology, Inc.)|Liminatus Pharma Inc. - Long-Term Debt to Capital|Lava Tx (LVTX) - Long-Term Debt to Equity|NXTC: Long-Term Debt to Capital Ratio|Long-Term Debt to Equity LPTX|Long-Term Liabilities to Capital Intensity Therapeutics, Inc.|Sensei Biotherapeutics Inc - Long-Term Debt to Equity Ratio|Long-Term Indebtedness to Equity Theriva Biologics Inc (TOVX)|Long-Term Debt to Equity Ratio Gritstone bio, Inc.|Long-Term Loans to Capital Ratio Kineta Corp (KA)|Long-Term Debt to Capital NexImmune, Inc.|Long-Term Debt to Capital Coefficient Turnstone Biologics Corp TSBX|VCNX (Vaccinex) - Long-Term Debt to Capital|HARP: Long-Term Liabilities to Capital